Petition Closed

Neuroendicrine cancer is a rare cancer with limited treatment options.  One proven treatment option is Lutate.

Lutate treatment can:
- shrink the cancer
- almost eliminate the cancer in some people
- has few side effects
- is an outpatient treatment.


If Lutate is given early in the disease, it can:
- stop the spread of the cancer
- allow people to remain productive
- minimise hospital admissions
- reduce demands on other expensive medical treatments and services.

In SA, WA, Qld and Victoria NET cancer patients are given Lutate as an early treatment option.  Due to funding limits Lutate is only available to NSW patients once they have exhausted all other treatment options and it is often given too late in the progression of the disease.  NSW patients are suffering more than patients in SA, WA, Qld and Victoria and risk dying prematurely because they can not access Lutate early enough in their disease.

It is estimated that $1.7 million would make Lutate treatment available to more than 100 NSW patients. Existing equipment and medical staff can deliver the treatment. No new equipment or staff is needed. St George Hospital and Royal North Shore Hospital are ready to provide Lutate treatment to all NSW neuroendocrine cancer patients.

Funding for the Lutate (lutetium177) is now the only requirement.

Letter to
Minister for Health, Minister for Medical Research The Hon. Jillian Skinner MP
Lutate has demonstrated very positive benefits for patients with neuroendocrine cancer when given as an early treatment option. It has been shown to shrink the cancer and almost eliminate the cancer in some people. Lutate has few side effects and is an outpatient treatment.
If Lutate is given early in the disease, it can stop the spread of the cancer; allow people to remain productive; minimise hospital admissions and reduce demands on other expensive medical treatments and services.

For the past decade Lutate treatment has been available to patients in Western Australia and Victoria early in their disease to stop the growth and spread of the cancer. It is now also available to South Australia and Queensland residents earlier in their disease.

Currently, in NSW, Lutate is only available to patients who have exhausted all other treatment options and is often given too late in the progression of the disease.

The NSW State government needs to fund this treatment until federal funding is available to:
- prevent neuroendocrine cancer patients in NSW from prematurely dying
- provide health equity for NSW patients
- keep neuroendocrine cancer patients out of hospital and healthier for longer
- maintain productivity, remain employed and able to care for their families
- ensure Lutate in NSW is provided according to medical need not financial availability

WHAT IS NEEDED to make Lutate available earlier to patients in NSW?
- funding for the Lutate (lutetium177) is now the only requirement
- it is estimated that $1.7 million would make Lutate treatment available to more than 100 NSW patients
- existing equipment and medical staff can deliver the treatment. No new equipment or staff is needed
- St George Hospital and Royal North Shore Hospital are ready to provide Lutate treatment to all NSW neuroendocrine cancer patients

PLEASE PROVIDE THE NECESSARY FUNDING TO SUPPORT LUTATE TREATMENT FOR NSW RESIDENTS WHO ARE FIGHTING TO SURVIVE NEUROENDOCRINE CANCER.

Thank you